Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 1;33(6):626-634.
doi: 10.1097/CCO.0000000000000787.

Mutational burden and immune recognition of gliomas

Diego Prost  1 , Franck Bielle  2 , Keith L Ligon  3   4   5   6 , Mehdi Touat  1   7
Affiliations
Review

Mutational burden and immune recognition of gliomas

Diego Prost et al. Curr Opin Oncol. .

Abstract

Purpose of review: Recent evidence suggests high tumor mutational burden (TMB-H) as a predictor of response to immune checkpoint blockade (ICB) in cancer. However, results in TMB-H gliomas have been inconsistent. In this article, we discuss the main pathways leading to TMB-H in glioma and how these might affect immunotherapy response.

Recent findings: Recent characterization of TMB-H gliomas showed that 'post-treatment' related to mismatch repair (MMR) deficiency is the most common mechanism leading to TMB-H in gliomas. Unexpectedly, preliminary evidence suggested that benefit with ICB is rare in this population. Contrary to expectations, ICB response was reported in a subset of TMB-H gliomas associated with constitutional MMR or polymerase epsilon (POLE) defects (e.g., constitutional biallelic MMRd deficiency). In other cancers, several trials suggest increased ICB efficacy is critically associated with increased lymphocyte infiltration at baseline which is missing in most gliomas. Further characterization of the immune microenvironment of gliomas is needed to identify biomarkers to select the patients who will benefit from ICB.

Summary: Intrinsic molecular and immunological differences between gliomas and other cancers might explain the lack of efficacy of ICB in a subset of TMB-H gliomas. Novel combinations and biomarkers are awaited to improve immunotherapy response in these cancers.

PubMed Disclaimer

Similar articles

  • Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma.
    Kang K, Xie F, Wu Y, Wang Z, Wang L, Long J, Lian X, Zhang F. Kang K, et al. Int Immunopharmacol. 2021 Jul;96:107610. doi: 10.1016/j.intimp.2021.107610. Epub 2021 Apr 10. Int Immunopharmacol. 2021. PMID: 33848908
  • Mechanisms and therapeutic implications of hypermutation in gliomas.
    Touat M, Li YY, Boynton AN, Spurr LF, Iorgulescu JB, Bohrson CL, Cortes-Ciriano I, Birzu C, Geduldig JE, Pelton K, Lim-Fat MJ, Pal S, Ferrer-Luna R, Ramkissoon SH, Dubois F, Bellamy C, Currimjee N, Bonardi J, Qian K, Ho P, Malinowski S, Taquet L, Jones RE, Shetty A, Chow KH, Sharaf R, Pavlick D, Albacker LA, Younan N, Baldini C, Verreault M, Giry M, Guillerm E, Ammari S, Beuvon F, Mokhtari K, Alentorn A, Dehais C, Houillier C, Laigle-Donadey F, Psimaras D, Lee EQ, Nayak L, McFaline-Figueroa JR, Carpentier A, Cornu P, Capelle L, Mathon B, Barnholtz-Sloan JS, Chakravarti A, Bi WL, Chiocca EA, Fehnel KP, Alexandrescu S, Chi SN, Haas-Kogan D, Batchelor TT, Frampton GM, Alexander BM, Huang RY, Ligon AH, Coulet F, Delattre JY, Hoang-Xuan K, Meredith DM, Santagata S, Duval A, Sanson M, Cherniack AD, Wen PY, Reardon DA, Marabelle A, Park PJ, Idbaih A, Beroukhim R, Bandopadhayay P, Bielle F, Ligon KL. Touat M, et al. Nature. 2020 Apr;580(7804):517-523. doi: 10.1038/s41586-020-2209-9. Epub 2020 Apr 15. Nature. 2020. PMID: 32322066 Free PMC article.
  • Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency.
    Das A, Tabori U, Sambira Nahum LC, Collins NB, Deyell R, Dvir R, Faure-Conter C, Hassall TE, Minturn JE, Edwards M, Brookes E, Bianchi V, Levine A, Stone SC, Sudhaman S, Sanchez Ramirez S, Ercan AB, Stengs L, Chung J, Negm L, Getz G, Maruvka YE, Ertl-Wagner B, Ohashi PS, Pugh T, Hawkins C, Bouffet E, Morgenstern DA. Das A, et al. Clin Cancer Res. 2023 Dec 1;29(23):4770-4783. doi: 10.1158/1078-0432.CCR-23-0411. Clin Cancer Res. 2023. PMID: 37126021 Free PMC article.
  • Hypermutation as a potential predictive biomarker of immunotherapy efficacy in high-grade gliomas: a broken dream?
    Gatto L, Franceschi E, Tosoni A, Nunno VD, Bartolini S, Brandes AA. Gatto L, et al. Immunotherapy. 2022 Jul;14(10):799-813. doi: 10.2217/imt-2021-0277. Epub 2022 Jun 7. Immunotherapy. 2022. PMID: 35670093 Review.
  • Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Li Y, Ma Y, Wu Z, Zeng F, Song B, Zhang Y, Li J, Lui S, Wu M. Li Y, et al. Front Immunol. 2021 Sep 29;12:751407. doi: 10.3389/fimmu.2021.751407. eCollection 2021. Front Immunol. 2021. PMID: 34659255 Free PMC article.
See all similar articles

Cited by

References

    1. Ostrom Q, Gittleman H, Liao P, et al. Neuro-Oncology CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United 2018; 19:1–88.
    1. Wen PY, Weller M, Lee EQ, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol 2020; 22:1073–1113.
    1. Weller M, van der Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 2021; 18:170–186.
    1. Weller M, van den Bent M, Tonn J, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol 2017; 18:e315–e329.
    1. Touat M, Idbaih A, Sanson M, et al. Glioblastoma targeted therapy: updated approaches from recent biological insights. Ann Oncol 2017; 7:1457–1472.

Publication types

Substances